Current and future therapies of hepatitis C

Clinics in Liver Disease

Volumn 5, Issue 2, 2001, Pages 335-360

  Shad, Javaid A ^a   McHutchison, John G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; AMINOTRANSFERASE; CONSENSUS INTERFERON; CYTOKINE; ENZYME INHIBITOR; INTERFERON; MERIMEPODIB; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS ENZYME; VIRUS RNA;

CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG RESPONSE; FATIGUE; FOLLOW UP; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; MONOTHERAPY; MYALGIA; REVIEW;

EID: 0035007727     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1089-3261(05)70169-0     Document Type: Review

References (102)

1. S. Abrignani M. Houghton H.H. Hsu Perspectives for a vaccine against hepatitis C virus J Hepatol 31 suppl 1 1999 259 263
2. A. Alberti L. Chemello F. Belussi Outcome of acute hepatitis C and role of interferon alpha therapy K. Nishioka H. Suzuki Viral Hepatitis and Liver Disease 1994 Springer Tokyo 604 606
3. A. Alberti L. Chemello F. Noventa Therapy of hepatitis C: Re-treatment with alpha-interferon Hepatology 26 1997 137S 142S
4. M.J. Alter Epidemiology of hepatitis C in the West Semin Liver Dis 15 1995 5 14
5. M.J. Alter Epidemiology of hepatitis C Hepatology 26 suppl 1 1997 62S 65S
6. M.J. Alter The epidemiology of acute and chronic hepatitis C Clin Liver Dis 1 1997 559 568
7. M.J. Alter D. Kruszon-Morgan O.V. Nainan The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
8. J. Arieas I. Pedroto T. Freitas Hepatitis C virus carriers with normal ALT activity: Viremia, genotype and effect of interferon therapy [abstract] Gastroenterology 110 1996 1144A
9. B. Bacon J.A. Rauscher N.L. Smith-Wilkaitis Interferon-ribavirin combination: Sustained response in previous monotherapy non-responders [abstract] Hepatology 30 1999 372A
10. J.M. Barrera M. Bruguera M.G. Ercilla Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C Hepatology 21 1995 639 644
11. L. Benvegnu G. Fattovich F. Noventa Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: A prospective study Cancer 74 1994 2442 2448
12. H.C. Bodenheimer K.L. Lindsay G.L. Davis Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial Hepatology 26 1997 473 477
13. H.L. Bonkovsky Therapy of hepatitis C: Other options Hepatology 26 suppl 1 1997 152S 155S
14. C. Camma V. Di Marco O. Lo Iacono Long-term course of interferon-treated chronic hepatitis C J Hepatol 28 1998 531 537
15. R.L. Carithers S.S. Emerson Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials Hepatology 25 suppl 1 1997 83S 88S
16. W.H. Caselmann S. Eisenhardt M. Alt Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C Intervirology 40 1997 394 399
17. L. Chemello L. Cavalletto E. Bernardinello The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C J Hepatol 23 1995 8 12
18. T. Chiba Y. Matsuzaki M. Abei The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma Am J Gastroenterol 91 1996 119 203
19. M. Cramp S. Rossol S. Chokshi Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C Gastroenterology 118 2000 346 355
20. G. Davis L.A. Balart E.R. Schiff Treatment of chronic hepatitis C with recombinant alpha-interferon: A multi-center randomized, controlled trial J Hepatol 11 1990 S31 S35
21. G.L. Davis R. Esteban-Mur V. Rustgi Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1493 1499
22. G.L. Davis J.Y. Lau Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 26 1997 122S 127S
23. G.L. Davis E. Schiff P. Marcellin Long-term continuous recombinant interferon alfa-2b (Intron-A) versus repeated 24-week cycles for disease suppression in IFN-relapsers with chronic hepatitis C [abstract] Hepatology 30 1999 317A
24. K.M. Detre S.H. Belle M. Lombardero Liver transplantation for chronic viral hepatitis Viral Hepatitis Reviews 2 1996 219 228
25. A.M. Di Bisceglie Hepatitis C and hepatocellular carcinoma Hepatology 26 suppl 1 1997 34S 38S
26. A.M. Di Bisceglie H.S. Conjeevaram M.W. Friedd Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 897 903
27. J.L. Dienstag NANB hepatitis I. Recognition, epidemiology and clinical features Gastroenterology 85 1983 439 462
28. V. Di Marco P.L. Almasio A. Vaccaro Combined treatment of relapse of chronic hepatitis C with high dose alpha-2b interferon plus ribavirin for 6 or 12 month [abstract] Hepatology 30 1999 303A
29. G. Dushieko J. Main H. Thomas Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study J Hepatol 25 1996 591 598
30. European Association for the Study of the Liver International Consensus Conference on Hepatitis C. Consensus statement J Hepatol 31 suppl 1 1999 3 8
31. G.C. Farrell B.R. Bacon R.D. Goldin Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial Hepatology 27 1998 1121 1127
32. H. Fernandez G. Banks R. Smith Ribavirin: A clinical overview Eur J Epidemiol 2 1986 1 14
33. T.L. Fong A.M. Di Bisceglie J.G. Waggoner The significance of antibody to hepatitis C virus in patients with chronic hepatitis B Hepatology 14 1991 64 67
34. B. Gavier M. Martinez-Gonzalez J. Riezu-Boj Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C Gastroenterology 113 1997 1647 1653
35. T. Giuberti M.G. Marin C. Ferrari Hepatitis C virus viremia following clinical resolution of acute hepatitis C J Hepatol 20 1994 666 671
36. P. Glue J.W. Fang R. Rouzier-Panis Pegylated interferon alfa-2b: Pharmacokinetics, phamacodynamics, safety and preliminary efficacy data. Hepatitis C Intervention Therapy Group Clin Pharmacol Ther 68 2000 556 567
37. E.J. Heathcote M.W. Fried M.A. Bain The pharmacokinetics of pegylated-40K interferon alpha-2A (PEG-IFN) in chronic hepatitis C (CHC) patients with cirrhosis [abstract] Gastroenterology 116 1999 A735
38. J. Heathcote M.L. Shiffman G. Cooksley Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
39. J. Heathcote M.L. Shiffman G. Cooksley Multinational evaluation of the efficacy and safety of once-weekly peginterferon alpha-2A (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis [abstract] Hepatology 30 1999 316A
40. T. Heintges J.R. Wands Hepatitis C virus: Epidemiology and transmission Hepatology 26 1997 521 526
41. J.H. Hoofnagle Hepatitis C: The clinical spectrum of disease Hepatology 26 suppl 1 1997 15S 20S
42. J.H. Hoofnagle D. Lau H. Conjeeveram Prolonged therapy of chronic hepatitis C with ribavirin J Viral Hepat 3 1996 1307 1312
43. C. Hultgren D.R. Milich O. Weiland The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses J Gen Virol 79 1998 2381 2391
44. R. Idilman N. Maria A. Colantoni Interferon treatment of cirrhotic patients with chronic hepatitis C J Viral Hepat 4 1997 81 91
45. E.B. Keeffe F.B. Hollinger Therapy of hepatitis C: Consensus interferon trials Hepatology 26 suppl 1 1997 101S 107S
46. R.S. Koff Therapy of hepatitis C: Cost-effectiveness analysis Hepatology 26 1997 152S 155S
47. K. Krawczynski M.J. Alter D.L. Tankersely Effect of immune globulin on the prevention of experimental hepatitis C virus infection J Infect Dis 173 1996 822 828
48. K. Krawczynski A. Fattom D. Culver Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees—trials of experimental immune treatment [abstract] Hepatology 30 1999 423A
49. M. Krüger C. Beger Q.-X. Li Identification of eIF2bγ and eIF2bγ as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach Proc Natl Acad Sci 97 2000 8566 8571
50. M.Y. Lai J.H. Kao P.M. Yang Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C Gastroenterology 111 1996 1307 1312
51. N.P. Lam A.U. Neumann D.R. Gretch Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 1997 226 231
52. P. Lampertico M. Rumi R. Romeo A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C Hepatology 19 1994 19 22
53. D.T. Lau D.E. Kleiner M.G. Ghany 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C Hepatology 28 1998 1121 1127
54. J.Y.N. Lau D.N. Standring Development of novel therapies for hepatitis C T.J. Liang J.H. Hoffnagle Biomedical Research Reports, Hepatitis C 2000 Academic Press 453 467
55. P.A. Lee L.M. Blatt K.S. Blanchard Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous administration in mice Hepatology 32 2000 640 664
56. W.M. Lee Therapy of hepatitis C: Interferon alfa-2a trials Hepatology 26 suppl 1 1997 89S 95S
57. D.G. Macejak K.L. Jensen S.F. Jamison Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes Hepatology 31 2000 769 776
58. M.P. Manns J.G. McHutchison S. Gordon Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial Hepatology [abstract] 32 2000 297A
59. P. Marcellin Hepatitis C: The clinical spectrum of the disease J Hepatol 31 suppl 1 1999 9 16
60. P. Marcellin N. Boyer A. Gervais Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann Intern Med 127 1997 875 881
61. P. Marcellin S. Levy J.P. Benhamou Management of the asymptomatic HCV carrier with normal ALT levels Viral Hepatitis Review 2 1996 277 283
62. P. Marcellin S. Levy S. Erlinger Therapy of hepatitis C: Patients with normal aminotransferase levels Hepatology 26 suppl 1 1999 133S 136S
63. P. Mathurin J. Moussalli J.F. Cadranel Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity Hepatology 27 1998 868 872
64. J.G. McHutchison S.C. Gordon E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
65. J.G. McHutchison L.M. Blatt R. Ponnudurai Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection J Med Virol 57 1999 351 355
66. J.M. McHutchison L. Blatt A. Sedghi-Vaziri Is there an optimal time to measure quantitative HCV RNA to predict non-response during interferon treatment for chronic HCV infection J Hepatol 29 1998 362 368
67. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C Hepatology 26 suppl 1 1997 2S 10S
68. J.G. McHutchison S.C. Gordon T. Morgan Predicting response to initial therapy with interferon alfa and ribavirin in chronic hepatitis C using serum HCV RNA during therapy [abstract] Hepatology 30 1999 365A
69. J.G. McHutchison T. Poynard Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C Semin Liver Dis 19 1999 57 65
70. D.R. Nelson G.Y. Lauwers J.Y. Lau A pilot study of recombinant human interleukin 10 (Tenovil) in patients with chronic hepatitis C who failed interferon-based therapy. [abstract] Hepatology 30 1999 189A
71. J.L. Patterson R. Fernandez-Larsson Molecular mechanisms of action of ribavirin Reviews in Infectious Diseases 12 1990 1139 1146
72. S. Pianko J.G. McHutchison Retreatment of hepatitis C patients who do not respond to interferon: The search continues Am J Gastroenterol 95 2000 1122 1124
73. T. Poynard P. Bedossa M. Chevallier A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group N Engl J Med 332 1995 1457 1462
74. T. Poynard P. Bedossa P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
75. T. Poynard V. Leroy M. Cohard Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C Hepatology 24 1996 778 789
76. T. Poynard V. Leroy P. Mathurin Treatment of chronic hepatitis C by interferon for longer duration than six months Dig Dis Sci 41 1996 99S 102S
77. T. Poynard P. Marcellin S. Lee Randomized trial of interferon alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus Lancet 352 1998 1426 1432
78. T. Poynard J. McHutchison Z. Goodman Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31 2000 211 218
79. O. Reichard G. Norkrans A. Fryden Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C Lancet 351 1998 1485 1492
80. J.A. Sandberg K.S. Speirer C.D. Sproul Subacute toxicity study of a ribozyme targeting VEGF receptor mRNA (ANGIOZYME) in female CD-1 mice Toxicol Sci 48 1999 175
81. S.W. Schalm J.T. Brouswer L. Chemello Interferon-ribavirin combination therapy for chronic hepatitis Dig Dis Sci 4 suppl 12 1996 131S 134S
82. S.W. Schalm B.E. Hansen L. Chemello Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers J Hepatol 26 1997 961 966
83. L.B. Seeff Natural history of hepatitis C Hepatology 26 suppl 1 1997 2S 10S
84. L. Serfaty H. Aumaitre O. Chazouilleres Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
85. M.L. Shiffman C.M. Hofmann E.B. Thompson Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
86. M. Shiffman P.J. Pockros R.K. Reddy A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alpha-2a (PEG) vs. standard alpha-2a for treatment of chronic hepatitis C [abstract] Gastroenterology 116 1999 A1275
87. D.M. Simon S.C. Gordon M.M. Kaplan Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open-label trial Hepatology 25 1997 445 448
88. R. Sobesky P. Mathurin F. Charlotte Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view Gastroenterology 116 1999 378 386
89. M. Takahashi G. Yamada R. Miyamoto Natural course of chronic hepatitis C Am J Gastroenterol 88 1993 240 243
90. M.J. Tong L.M. Blatt J.G. McHutchison Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison Hepatology 26 1997 1640 1645
91. M.J. Tong K.R. Reddy W.M. Lee Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial Hepatology 26 1997 747 754
92. Trepo C, Lindsay K, Niederau C, et al. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron A) for treatment of chronic hepatitis C [abstract]. J Hepatol, in press
93. R. Vinayek A.O. Shakil Adverse events associated with interferon alfa therapy in patients with chronic viral hepatitis Viral Hepatitis Reviews 3 1997 167 177
94. J.B. Wong W.G. Bennett R.S. Koff Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs JAMA 280 1998 2088 2093
95. T. Wright M.L. Shiffman S. Knox Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with chronic hepatitis C [abstract] Hepatology 30 1999 408A
96. Z.-X. Xu J. Hoffman I. Patel Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon alpha-2a (IFN alpha-2a) to healthy subjects Hepatology 28 1998 702A
97. M. Yano H. Kumada M. Kage The long-term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
98. Z.M. Younossi R.P. Perrillo The roles of amantidine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C Semin Liver Dis 19 suppl 1 1999 95 102
99. S. Zeuzem S.V. Feinman J. Rasenack Peginterferon alfa–2A in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
100. S. Zeuzem S.V. Feinman J. Rasenack M.-Y. Lai Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
101. S. Zeuzem U. Hopf V. Carreno A phase I/II study of interleukin-12 in patients with chronic hepatitis C Hepatology 29 1999 1280 1287
102. N. Zitzman A.S. Mehta S. Carrouee Imino sugars inhibit the formation and secretion of bovine viral diarrheal virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents Proc Natl Acad Sci 96 1999 11878 11882